Literature DB >> 20606967

A current perspective on leishmaniasis.

Angela Clem1.   

Abstract

There are many challenges facing the successful control and eradication of cutaneous and visceral leishmaniasis. Leishmaniasis is still endemic in many poverty stricken and war torn areas. Through the use of an extensive literature review, this article examined the global disease burden of cutaneous and visceral leishmaniasis. Surveillance and control measures for leishmaniasis being used by the World Health Organization were also discussed in this article. Finally, potential new treatments and possible vaccines for leishmaniasis were reviewed in this article.

Entities:  

Keywords:  Cutaneous leishmaniasis; Treatments; Vaccines; Visceral leishmaniasis

Year:  2010        PMID: 20606967      PMCID: PMC2889651          DOI: 10.4103/0974-777X.62863

Source DB:  PubMed          Journal:  J Glob Infect Dis        ISSN: 0974-777X


  5 in total

1.  Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells.

Authors:  Subha Banerjee; June Ghosh; Subha Sen; Rajan Guha; Ranjan Dhar; Moumita Ghosh; Sanchita Datta; Bikramjit Raychaudhury; Kshudiram Naskar; Arun Kumar Haldar; C S Lal; K Pandey; V N R Das; Pradeep Das; Syamal Roy
Journal:  Infect Immun       Date:  2009-03-16       Impact factor: 3.441

2.  Novel arylimidamides for treatment of visceral leishmaniasis.

Authors:  Michael Zhuo Wang; Xiaohua Zhu; Anuradha Srivastava; Qiang Liu; J Mark Sweat; Trupti Pandharkar; Chad E Stephens; Ed Riccio; Toufan Parman; Manoj Munde; Swati Mandal; Rentala Madhubala; Richard R Tidwell; W David Wilson; David W Boykin; James Edwin Hall; Dennis E Kyle; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

3.  The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells.

Authors:  Susana Mendez; Ryan Traslavina; Meleana Hinchman; Lu Huang; Patricia Green; Michael H Cynamon; John T Welch
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

4.  Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis.

Authors:  Xenón Serrano-Martín; Gilberto Payares; Marisel De Lucca; Juan Carlos Martinez; Alexis Mendoza-León; Gustavo Benaim
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

5.  Cellular and humoral responses to Leishmania major virulence factors in healed cutaneous leishmaniasis and Mediterranean visceral leishmaniasis patients.

Authors:  Inès Lakhal-Naouar; Thouraya Boussoffara; Amel Meddeb-Garnaoui; Yosser Ben Achour-Chenik; Hechmi Louzir; Mehdi Chenik
Journal:  Clin Vaccine Immunol       Date:  2009-04-01
  5 in total
  13 in total

1.  Epidemiological features of cutaneous leishmaniasis endemic in hilly areas of district Karak, Khyber-Pakhtunkhwa province of Pakistan.

Authors:  Mehboob Nawaz; Misbahud Din; Ayyaz Khan; Asad Khan; Muhammad Ali; Siraj Ud Din; Khalid Aslam
Journal:  J Parasit Dis       Date:  2020-07-23

2.  Old World cutaneous leishmaniasis: diagnosis and treatment.

Authors:  Abderrahmen Masmoudi; Wala Hariz; Slaheddine Marrekchi; Mariem Amouri; Hamida Turki
Journal:  J Dermatol Case Rep       Date:  2013-06-30

Review 3.  Telehealth: a perspective approach for visceral leishmaniasis (kala-azar) control in India.

Authors:  Gouri Sankar Bhunia; Shreekant Kesari; Nandini Chatterjee; Vijay Kumar; Pradeep Das
Journal:  Pathog Glob Health       Date:  2012-07       Impact factor: 2.894

4.  Leishmania donovani reduces the levels of retinoic acid-synthesizing enzymes in infected macrophages and favoring its own survival.

Authors:  Pankaj Verma; Amit Kumar Kureel; Sheetal Saini; Satya Prakash; Smita Kumari; Sarath Kumar Kottarath; Sandeep Kumar Srivastava; Madhusudan Bhat; Amit Kumar Dinda; Chandreshwar Prasad Thakur; Shivesh Sharma; Ambak Kumar Rai
Journal:  Parasitol Res       Date:  2018-10-18       Impact factor: 2.289

5.  Copaiba Oil: An Alternative to Development of New Drugs against Leishmaniasis.

Authors:  Adriana Oliveira Dos Santos; Tânia Ueda-Nakamura; Benedito Prado Dias Filho; Valdir Florêncio da Veiga Junior; Celso Vataru Nakamura
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-12       Impact factor: 2.629

Review 6.  Measures to Control Phlebotomus argentipes and Visceral Leishmaniasis in India.

Authors:  DeAnna C Bublitz; Richard M Poché; Rajesh Garlapati
Journal:  J Arthropod Borne Dis       Date:  2016-01-05       Impact factor: 1.198

7.  Carboxylate derivatives of tributyltin (IV) complexes as anticancer and antileishmanial agents.

Authors:  Durdana Waseem; Arshad Farooq Butt; Ihsan-Ul Haq; Moazzam Hussain Bhatti; Gul Majid Khan
Journal:  Daru       Date:  2017-04-04       Impact factor: 3.117

8.  An NLRP3 inflammasome-triggered Th2-biased adaptive immune response promotes leishmaniasis.

Authors:  Prajwal Gurung; Rajendra Karki; Peter Vogel; Makiko Watanabe; Mark Bix; Mohamed Lamkanfi; Thirumala-Devi Kanneganti
Journal:  J Clin Invest       Date:  2015-02-17       Impact factor: 14.808

9.  Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection.

Authors:  Sandip Mukherjee; Budhaditya Mukherjee; Rupkatha Mukhopadhyay; Kshudiram Naskar; Shyam Sundar; Jean Claude Dujardin; Anjan Kumar Das; Syamal Roy
Journal:  PLoS Negl Trop Dis       Date:  2012-12-27

10.  Deficiency of p110δ isoform of the phosphoinositide 3 kinase leads to enhanced resistance to Leishmania donovani.

Authors:  Forough Khadem; Zhirong Mou; Dong Liu; Sanjay Varikuti; Abhay Satoskar; Jude E Uzonna
Journal:  PLoS Negl Trop Dis       Date:  2014-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.